-+ 0.00%
-+ 0.00%
-+ 0.00%

Rothschild & Co Downgrades Medpace Hldgs to Neutral, Raises Price Target to $474

Benzinga·09/03/2025 15:19:18
Listen to the news
Rothschild & Co analyst Jamie Clark downgrades Medpace Hldgs (NASDAQ:MEDP) from Buy to Neutral and raises the price target from $342 to $474.